Answers are grounded in this paper and cite their sources.
Objectiveat present, there remains controversy regarding the clinical efficacy of Corbrin (Bailing) capsules in the treatment of renal insufficiency (RI). A meta-analytic approach was adopted in this study to assess the clinical efficacy of Corbrin capsules for treating RI, aiming to provide a certain level of clinical evidence to guide the selection of RI therapeutic interventions.Methodsthe meta-analysis was conducted on databases containing PubMed, CNKI, Weipu Database, Cochrane Library and Wanfang until January 2023. The search for relevant studies was conducted without language restrictions. The study encompassed a randomized controlled trial that examined the efficacy of Corbrin capsules in treating RI. Blood urea nitrogen (BUN), serum creatinine (Scr), 24-hour urine protein quantity (24 h UPQ), and estimated creatinine clearance (ECC) were amalgamated using standardized mean difference (SMD) and its corresponding 95% confidence interval (CI). Meanwhile, the treatment effect (TE) outcome was aggregated using odds ratio (OR) and its corresponding 95% CI. To evaluate heterogeneity, the Q test and I2 statistics were employed within a random-effects model framework.Resultsa total of 11 eligible articles were included, involving 1,100 patients (594 in the Corbrin capsule group and 516 in the control group). Compared with control subjects, the SMD was-1.3532 for Ser (95% CI: -2.0617– -0.6448), -1.7868 for UPQ (95% CI: -2.8901– -0.6836), -1.3302 for BUN (95% CI: -2.2428– -0.4176), and 1.7842 for ECC (95% CI: 0.6774–2.8910). TE had an OR of 1.9786 (95% CI: 0.7153–5.4734), and publications were not found to be biased (t=0.5627, P=0.6738).ConclusionIn RI patients, Corbrin capsule has a relatively good therapeutic effect.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: